The invention relates to predicting cancer relapse or predicting patient survival by determining a level of serum thymidine kinase 1 (STK1) material in a body sample from a patient diagnosed with hematological cancer using an antibody or a fragment thereof specifically binding to a serum form of human TK1. The determined level of STK1 material is compared with a threshold value selected based on an age of the patient. Cancer relapse is then predicted based on the comparison.

Monoclonal antibodies and fragments thereof are capable of binding to a serum form of human TK1. Kits and methods involve the use of such monoclonal antibodies or fragments.

Disclosed are the expression of a recombinant chicken IgY scFv antibody and monoclonal antibody raised against human thymidine kinase 1 (hTK1) in prokaryotic cells and a preparation method and use thereof. The scFv antibody includes an amino acid sequence shown in SEQ ID NO: 1. The anti-hTK1 recombinant scFv antibody and monoclonal antibody have good immunoreactivity, high specificity and sensitivity, and are easy to separate and purify.

Disclosed are the development of a recombinant chicken IgY monoclonal antibody and a recombinant chicken IgY single-chain variable fragment (scFv) antibody raised against human thymidine kinase 1 in mammalian cells and a preparation method and use thereof. A light chain of the scFv antibody includes an amino acid sequence shown in SEQ ID NO: 1, and a heavy chain of the scFv antibody includes an amino acid sequence shown in SEQ ID NO: 2.

Disclosed are a chicken-derived recombinant full-length monoclonal IgY antibody against human TK1 and applications thereof. Through an improved phage display method, a human TK1 C-terminal 195-225 polypeptide was used to develop a chicken-derived recombinant full-length monoclonal IgY antibody against human TK1. A 3.410.sup.9 pfu/mL ultra-large library was quickly constructed within three weeks, with a positive cloning rate of up to 98%. ELISA, immunoblotting and immunohistochemical detection methods were used to identify a preferred hTK1-IgY-rmAb antibody with high specificity and high sensitivity. The invention improves the stability of antibody batches, realizes the operation of a new generation of TK1 detection kit based on recombinant IgY antibodies on a fully automatic chemiluminometer, and can meet the detection needs of large-scale early tumor risk screening.

A kit useful for determination of canine TK1 in a sample is disclosed. The kit comprises a first monoclonal antibody, or a fragment thereof, immobilized to a support or intended to be immobilized to a support. The kit also comprises a second monoclonal antibody, or a fragment thereof. One of the monoclonal antibodies has specificity for a peptide consisting of an amino acid sequence from a C-terminal region of canine TK1 and the other monoclonal antibody has specificity for a peptide consisting of an amino acid sequence from an active site of TK1.